Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?
Current opinion in pharmacology
2018; 42: 55?61
Using iPSC Models to Probe Regulation of Cardiac Ion Channel Function
CURRENT CARDIOLOGY REPORTS
2018; 20 (7): 57
Cardiovascular disease remains the largest single cause of mortality in the Western world, despite significant advances in clinical management over the years. Unfortunately, the development of new cardiovascular medicines is stagnating and can in part be attributed to the difficulty of screening for novel therapeutic strategies due to a lack of suitable models. The advent of human induced pluripotent stem cells and the ability to make limitless numbers of cardiomyocytes could revolutionize heart disease modeling and drug discovery. This review summarizes the state of the art in the field, describes the strengths and weaknesses of the technology, and applications where the model system would be most appropriate.
View details for DOI 10.1016/j.coph.2018.07.003
View details for PubMedID 30081259
Cardiovascular disease is the leading contributor to mortality and morbidity. Many deaths of heart failure patients can be attributed to sudden cardiac death due primarily to ventricular arrhythmia. Currently, most anti-arrhythmics modulate ion channel conductivity or ?-adrenergic signaling, but these drugs have limited efficacy for some indications, and can potentially be proarrhythmic.Recent studies have shown that mutations in proteins other than cardiac ion channels may confer susceptibility to congenital as well as acquired arrhythmias. Additionally, ion channels themselves are subject to regulation at the levels of channel expression, trafficking and post-translational modification; thus, research into the regulation of ion channels may elucidate disease mechanisms and potential therapeutic targets for future drug development. This review summarizes the current knowledge of the molecular mechanisms of arrhythmia susceptibility and discusses technological advances such as induced pluripotent stem cell-derived cardiomyocytes, gene editing, functional genomics, and physiological screening platforms that provide a new paradigm for discovery of new therapeutic targets to treat congenital and acquired diseases of the heart rhythm.
View details for DOI 10.1007/s11886-018-1000-0
View details for Web of Science ID 000433260900006
View details for PubMedID 29802473